Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-CS
NCT07617675Phase 4Not yet recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- May 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute kidney injury (AKI) comparing rhBNP Treatment Group with Placebo Control Group (2 arms). Primary endpoint: Incidence of acute kidney injury (AKI) within 7 days postoperatively. Planned start May 2026; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT07617675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617675.